Back
Monopar Therapeutics, Inc. Stock Predictions
14K Investors Got In Earlier. You Still Can.
DISCLOSURE: This is a paid advertisement for RAD Intel's Reg A offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks at invest.radi
Sell
39
MNPR
Monopar Therapeutics, Inc.
Last Price:
$76.65
Seasonality Move:
36.18%
7 Day Trial
ALL ACCESS PASS
$
7
Share Price Moved. Momentum Hasn't Slowed.
DISCLOSURE: This is a paid advertisement for RAD Intel's Reg A offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks at invest.radiMonopar Therapeutics, Inc. Stock Forecast
-
Over the next 52 weeks, Monopar Therapeutics, Inc. has on average historically risen by 222.6% based on the past 5 years of stock performance.
-
Monopar Therapeutics, Inc. has risen higher in 2 of those 5 years over the subsequent 52-week period, corresponding to a historical accuracy of 40%
-
Is Monopar Therapeutics, Inc. Stock Undervalued?The current Monopar Therapeutics, Inc. [MNPR] share price is $74.61. The Score for MNPR is 39, which is 22% below its historic median score of 50, and infers higher risk than normal.
-
MNPR is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.
Will Monopar Therapeutics, Inc. Stock Go Up Next Year?
-
Over the next 52 weeks, Monopar Therapeutics, Inc. has on average historically risen by 222.6% based on the past 5 years of stock performance.
Monopar Therapeutics, Inc. Stock Rating
Sell
39
Monopar Therapeutics, Inc. (MNPR)
is a Sell
Is Monopar Therapeutics, Inc. overpriced?
-
Monopar Therapeutics, Inc. has risen higher in 2 of those 5 years over the subsequent 52-week period, corresponding to a historical accuracy of 40%
Monopar Therapeutics, Inc. Stock Price History
Stock Information
Stock Info
Exchange:
NASDAQ
Country:
United States
Industry:
Biotechnology
Sector:
Health Care
Type:
stock
Website:
monopartx.com
52-Week Data
52-Week High:
105.00
52-Week Low:
21.00
Prediction Charts
Market Cap:
498.6M
Price in USD:
74.61
Volume:
248.7K
Beta:
1.40
Technical Analysis
SMA50:
84.43
SMA100:
66.11
SMA200:
51.38
52-Wk Change:
207.65%
Stock Predictions
-
Is Monopar Therapeutics, Inc. stock public?Yes, Monopar Therapeutics, Inc. is a publicly traded company.
-
What is the Monopar Therapeutics, Inc. stock quote today?The Monopar Therapeutics, Inc. stock price is 74.61 USD today.
-
How to buy Monopar Therapeutics, Inc. stock online?You can buy Monopar Therapeutics, Inc. shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
14-Day Historical Data
| Date | Opening | Closing | Minimum | Maximum |
|---|---|---|---|---|
| Nov-24 | 92.94 | 92.75 | 100.50 | 90.00 |
| Nov-25 | 93.06 | 88.47 | 98.00 | 85.91 |
| Nov-26 | 88.03 | 87.36 | 88.88 | 83.86 |
| Nov-28 | 87.66 | 86.18 | 91.79 | 84.00 |
| Dec-1 | 84.88 | 83.06 | 87.97 | 82.27 |
| Dec-2 | 83.48 | 75.94 | 84.04 | 75.69 |
| Dec-3 | 77.48 | 77.19 | 79.65 | 74.00 |
| Dec-4 | 75.47 | 79.47 | 79.90 | 75.47 |
| Dec-5 | 79.79 | 80.38 | 85.01 | 79.50 |
| Dec-8 | 80.40 | 76.43 | 83.87 | 75.27 |
| Dec-9 | 76.82 | 75.44 | 78.95 | 74.51 |
| Dec-10 | 75.13 | 78.22 | 79.31 | 74.85 |
| Dec-11 | 78.72 | 77.05 | 79.02 | 75.00 |
| Dec-12 | 76.51 | 74.61 | 76.90 | 73.63 |
Monopar Therapeutics, Inc. Earnings
Monopar Therapeutics, Inc. Earnings Report: Per Share Monopar Therapeutics, Inc. Earnings Q1 Q2 Q3 and Q4 last year and next year.
Monopar Therapeutics, Inc. Forecast Revenue Growth
Monopar Therapeutics, Inc. Stock Analysis: Historical quarterly revenues per share for Monopar Therapeutics, Inc. and historical quarterly revenue growth:
-
Analysts estimate an earnings increase this quarter of $0.58 per share, a decrease next quarter of $0.00 per share, an increase this year of $0.10 per share, and a decrease next year of $1.78 per share.
* Monopar Therapeutics, Inc. stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.